Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging database aims to sharpen Parkinson's diagnosis

NCT ID NCT06828705

Knowledge-focused Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study created the first international database of Datscan imaging values from 300 patients. The goal was to help doctors better diagnose Parkinson's disease and other neurodegenerative conditions by comparing brain scan results. Researchers hope this database will improve diagnostic accuracy and potentially replace older imaging methods.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this database could help doctors more accurately diagnose Parkinson's disease and distinguish it from other conditions with similar symptoms.
What could go wrong
This is a database study, not a treatment trial. It may not lead to immediate clinical changes, and the results may not apply to all imaging equipment or patient populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

300 people

The number who actually took part.

Started

Jul 2025

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients who have undergone a Datscan® scintigraphy on the VERITON-CT camera in the nuclear medicine department of the Nancy University Hospital and who have an established clinical diagnosis, in the absence of neurodegenerative pathology or Parkinson's disease or Lewy body disease

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients who have undergone a Datscan scintigraphy on the VERITON camera in the nuclear medicine department of the Nancy University Hospital and who have an established clinical diagnosis, -Absence of neurodegenerative pathology or Parkinson's disease or Lewy body disease. * The clinical diagnosis can only be established after two years of clinical follow-up. Exclusion Criteria: * Excluded from this research will be the patients opposed to the use of their data, minors, atypical Parkinsonian syndromes, * patients who died before two years of clinical follow-up, * patients who had their Datscan examination carried out on a camera other than the VERITON and - patients lost to follow-up.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lewy body disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Lewy body dementia neurodegenerative disease Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neurodegenerative diseases

Contacts and locations

Locations

  • CHRU NANCY Brabois, nuclear medicine department

    Vandœuvre-lès-Nancy, 54511, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.